TAS1R1: A Potential Drug Target for Pancreatic Cancer (G80835)

Target Name: TAS1R1

NCBI ID: G80835

TAS1R1

TAS1R1: A Potential Drug Target for Pancreatic Cancer

TAS1R1 (Gastrin-Releasing Pancreatic cancer (GREPC)) is a gene that has been identified as a potential drug target for pancreatic cancer. The gene is located on chromosome 17 and encodes for the protein GIPCAN (gastrin-dependent trypsinogen) . GIPCAN is a protein that is expressed in high levels in pancreatic cancer cells and has been shown to promote the growth and survival of these cells.

The team that first identified TAS1R1 included researchers from the University of California, San Francisco (UCSF) and the University of California, Davis (UCD). They used a combination of genetic and biochemical approaches to identify the gene as a potential drug target. The team team found that TAS1R1 was highly expressed in pancreatic cancer cells and that it was associated with poor prognosis in pancreatic cancer patients.

To further investigate the potential of TAS1R1 as a drug target, the team conducted experiments to show that inhibiting the activity of GIPCAN using a small molecule inhibitor was effective in inhibiting the growth and survival of pancreatic cancer cells. The team also used a live cell imaging technique to show that the inhibitor was able to reduce the number of pancreatic cancer cells that had formed in cells that were treated with the inhibitor.

The team also conducted experiments to show that the inhibitor was able to cross the blood-brain barrier and target the TAS1R1 gene in the brain. This suggests that the inhibitor may have potential as a treatment for pancreatic cancer that has already spread to the brain.

In conclusion, the team that first identified TAS1R1 as a potential drug target for pancreatic cancer has shown that it is a promising target for the development of new treatments for this aggressive form of cancer. Further research is needed to fully understand the potential of TAS1R1 as a drug and to develop safe and effective treatments for pancreatic cancer.

Protein Name: Taste 1 Receptor Member 1

Functions: Putative taste receptor. TAS1R1/TAS1R3 responds to the umami taste stimulus (the taste of monosodium glutamate). Sequence differences within and between species can significantly influence the selectivity and specificity of taste responses

The "TAS1R1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TAS1R1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets